Nov 14 (Reuters)- Brightpath Biotherapeutics Co., Ltd. PARENT-ONLY FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2025 Sep 30, 2024 Mar 31, 2026 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 0 mln 0 mln 0 mln (-40.0 pct) (+25.0 pct) (-87.6 pct) Operating loss 464 mln loss 542 mln loss 1.18 Recurring loss 460 mln loss 537 mln loss 1.16 Net loss 462 mln loss 538 mln loss 1.17 EPS loss 4.53 yen loss 7.11 yen loss 12.88 yen Ann Div NIL NIL -Q2 div NIL NIL -Q4 div NIL NIL NOTE - Brightpath Biotherapeutics Co., Ltd.. To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T